Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value

Mathews, Rebecca, Hall, Wayne and Carter, Adrian (2012) Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. Addiction, 107 12: 2069-2074. doi:10.1111/j.1360-0443.2012.03836.x

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ287821_OA.pdf Full text (open access) application/pdf 72.82KB 2

Author Mathews, Rebecca
Hall, Wayne
Carter, Adrian
Title Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value
Journal name Addiction   Check publisher's open access policy
ISSN 0965-2140
1360-0443
Publication date 2012-12
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/j.1360-0443.2012.03836.x
Open Access Status File (Author Post-print)
Volume 107
Issue 12
Start page 2069
End page 2074
Total pages 6
Place of publication West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2013
Language eng
Formatted abstract
Genetic research on addiction liability and pharmacogenetic research on treatments for addiction have identified some genetic variants associated with disease risk and treatment. Genetic testing for addiction liability and treatment response has not been used widely in clinical practice because most of the genes identified only modestly predict addiction risk or treatment response. However, many of these genetic tests have been commercialized prematurely and are available direct to the consumer (DTC). The easy availability of DTC tests for addiction liability and lack of regulation over their use raises a number of ethical concerns. Of paramount concern is the limited predictive power and clinical utility of these tests. Many DTC testing companies do not provide the consumer with the necessary genetic counselling to assist them in interpreting and acting on their test results. They may also engage in misleading marketing to entice consumers to purchase their products. Consumers' genetic information may be vulnerable to misuse by third parties, as there are limited standards to protect the privacy of the genetic information. Non-consensual testing and inappropriate testing of minors may also occur. The United States Food and Drug Administration plans to regulate DTC genetic tests. Based on the ethical concerns we discuss below, we believe there is a strong case for regulation of DTC genetic tests for addiction liability and treatment response. We argue that until this occurs, these tests have more potential to cause harm than to contribute to improved prevention and treatment of addiction
Keyword Addiction
Advertising
Direct to consumer
Ethics
Genetic testing
Prevention
Susceptibility
Treatment
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: UQ Centre for Clinical Research Publications
Official 2013 Collection
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 23 Dec 2012, 00:58:14 EST by System User on behalf of UQ Centre for Clinical Research